A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

The present invention relates to a method of capturing and stabilising volatile thiol malodour generated on the human skin, comprising steps of: i) contacting the human skin with a substrate, ii) absorbing said thiol into the substrate, and iii) reacting said thiol with a thiol-capture agent. The invention also relates to a method of quantifying said thiol, a method of assessing the deodorizing performance of a cosmetic composition on the human skin.

Compositions and kits for oral administration of a phosphodiesterase-4 (PDE4) inhibitor and one or more additional active agents that reduces or eliminates a side effect associated with the PDE4 inhibitor are provided. Also provided are methods for use of these compositions and kits for treating conditions treatable with a PDE4 inhibitor therapy and for increasing patient compliance with treatment with PDE4 inhibitors.

Compositions and kits for oral administration of a phosphodiesterase-4 (PDE4) inhibitor and one or more additional active agents that reduces or eliminates a side effect associated with the PDE4 inhibitor are provided. Also provided are methods for use of these compositions and kits for treating conditions treatable with a PDE4 inhibitor therapy and for increasing patient compliance with treatment with PDE4 inhibitors.

The disclosure provides methods for rescuing synaptic defects caused by abnormal MeCP2 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a nootropic agent and/or an alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, MECP2-mosaic neurospheres, and cortical organoids).

The disclosure provides methods for rescuing synaptic defects caused by abnormal MeCP2 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a nootropic agent and/or an alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, MECP2-mosaic neurospheres, and cortical organoids).

The disclosure provides methods for rescuing synaptic defects caused by abnormal MeCP2 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a nootropic agent and/or an alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, MECP2-mosaic neurospheres, and cortical organoids).

The present invention provides methods treating multiple sclerosis (MS) in a patient in need of treatment thereof. The methods comprise co-administering to the patient a fumarate or pharmaceutical acceptable salt thereof, and at least one sulfonylurea or pharmaceutical acceptable salt thereof, where the amount of the fumarate is administered at a dose lower than the therapeutically effective dose if the fumarate is administered alone.

The present invention provides methods treating multiple sclerosis (MS) in a patient in need of treatment thereof. The methods comprise co-administering to the patient a fumarate or pharmaceutical acceptable salt thereof, and at least one sulfonylurea or pharmaceutical acceptable salt thereof, where the amount of the fumarate is administered at a dose lower than the therapeutically effective dose if the fumarate is administered alone.